Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case : MECHANISM-Elective
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- Kobe University
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Rate of stent-strut coverage determined by OCT.
- Last Updated
- 8 years ago
Overview
Brief Summary
To treat patients with stable coronary artery disease, elective percutaneous coronary intervention (PCI) will be performed with the use of an everolimus-eluting cobalt- chromium stent (everolimus-eluting stent: EES, Xience Prime, Xpedition), which is the current standard drug-eluting stent (DES). Vascular responses at the site of stent placement will be evaluated by optical coherence tomography (OCT) at 1 or 3 months and at 12 months after stent placement, along with observation of changes over time in the target vessel. The relationships between OCT findings and the time course of platelet aggregation and between OCT findings and the occurrence of major cardio- cerebrovascular events will also be elucidated.
Investigators
Toshiro Shinke, MD, PhD
Associate Professor
Kobe University
Eligibility Criteria
Inclusion Criteria
- •Patients having at least one de novo lesion in a coronary artery in whom PCI with a DES is indicated
- •Patients aged 20 to less than 85 years at the time of informed consent
- •Patients who have provided informed consent written by themselves
- •Patients who are able to undergo OCT examinations of the site of stent placement at 1 or 3 months and at 12 months
Exclusion Criteria
- •If it is judged difficult to perform clinical and angiographic follow-up at 12 months (considering the patient's remote place of residence, etc.)
- •Patients with acute myocardial infarction (AMI)
- •Patients in a state of shock
- •Patients with cardiac failure
- •Patients having a culprit lesion in the left main coronary artery trunk
- •Patients having a lesion with a reference vessel diameter of less than 2.0 mm or 4.5 mm or larger by visual estimate
- •Patients having an in-stent restenosis lesion as the culprit lesion
- •Patients having chronic renal failure with a serum creatinine level of 2.0 mg/dL or higher at a screening visit
- •Patients on hemodialysis
- •Cancer patients with a life expectancy of less than 2 years
Outcomes
Primary Outcomes
Rate of stent-strut coverage determined by OCT.
Time Frame: 3 months
Rate of stent-strut coverage determined by OCT at 3 months after stent placement (To observe temporal course from the early stage, the rate of stent-strut coverage in the 1-month arm will also be evaluated in a complementary manner, separately from the 3-month arm.) To identify the factors defining the strut coverage at 1-month or 3-months, from OCT index, blood markers, platelet aggregation test immediately after stenting, the strut coverage of 1 to 3 months
Secondary Outcomes
- Any TLR(1-year)
- CABG(1 year)
- Any revascularization(1 year)
- Clinically-driven TLR(1 year)
- Angiographic binary restenosis(12 month)
- The percentage of stent strut coverage by OCT(12 month)
- Angiographic Quantitative analysis(12 month)
- All-cause Death, Cardiac death, MI, Stroke, Major bleeding(1-year)
- Any TVR(1 year)
- Patient-oriented composite(1 year)
- OCT endpoint(1-month or 3-month)
- Angiographic Qualitative analysis(12 month)